Xspray Pharma Partners with EVERSANA® for U.S. Cancer Treatment Launch

Written By Olivia Rönnlöv

Xspray Pharma Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL).

Olivia Rönnlöv
Sign up to read this post
Join Now
Previous

Despite Headwinds, the Transatlantic Economy Set New Records in 2022
Next

United States and the European Commission announce launch of the Clean Energy Incentives Dialogue